CERo Therapeutics (CERO) Holdings announces that Sarah Cannon Research Institute, SCRI, at Colorado Blood Cancer Institute, CBCI, in Denver, Colorado will be a key clinical trial site for the Company’s Phase 1 clinical trial of CER-1236. Partnering with SCRI to advance cancer research, CBCI is the region’s leader in blood cancer care and serves a seven-state region. The trial is focused on patients with acute myeloid leukemia, AML, and patient enrollment is underway with first dosing of the initial cohort of patients expected by June. Chris Ehrlich, CERo Therapeutics CEO added, “CBCI is a world-renowned cancer center, and we believe their participation in our AML trial is continued validation of the scientific work performed to date with CER-1236. We look forward to announcing enrollment and initial dosing in the near term for this trial and to progress in launching our solid tumor study.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERO:
- Cero Therapeutics enters securities purchase agreement for up to $8M
- Cero Therapeutics initiated with a Buy at D. Boral Capital
- Cero Therapeutics announces critical patent application allowances from USPTO
- Cero announces initial clinical trial site for Phase 1 trial of CER-1236
- CERo Therapeutics Delays Yearly Report Filing